/
Infectious Disease
Respiratory Syncytial Virus (RSV)
23
Pipeline Programs↗
46
Active Trials↗
27
Companies Involved↗
Respiratory Syncytial Virus (RSV) is an emerging landscape with 23 programs across 27 companies. The most active players are Moderna, Pfizer, MAXVAX Biotechnology Limited Liability Company. 7 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical8
Phase 13
Phase 25
Phase 37
Approved
No programs
Analysis
Modality Breakdown
11programs
Vaccine655%
Small molecule218%
RNA therapy218%
Monoclonal antibody19%
Modality classified for 70% of 23 pipeline programs.
Analysis
Trial Status
167
clinical trials
Completed95 · 57%
Active, not recruiting25 · 15%
Terminated19 · 11%
Recruiting15 · 9%
Not yet recruiting6 · 4%
Unknown status3 · 2%
Other4 · 2%
Clinical Trials
Trial Activity
167 trials
A Phase 1, Randomized, Double-Blind, Ascending-Dose Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Respiratory Syncytial Virus mRNA Vaccine YKYY025 Injection in Healthy Adult Participants
Recruiting·BBeijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.·Phase 1·NCT07694557·180 enrolled
Page 1 of 12
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)